Kinetics of the Finasteride Prostate Induced Apoptosis

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00130767

Enrollment

Registered

2005-08-16

Start date

2004-12-31

Completion date

Unknown

Last updated

2007-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Keywords

Prostate, apoptosis, finasteride kinetics

Brief summary

The aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (BPH). Five sets of patients who need a surgical procedure because of low tract urinary symptoms are randomly attributed to one of five sets of treatment: 0, 7, 14, 21 or 28 days of finasteride treatment before the day of the procedure. Prostate histological fragments are conditioned for molecular and histologic studies.

Interventions

DRUGfinasteride

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

40 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Patients with low tract urinary symptoms needing a surgical procedure * No previous treatment with finasteride * No androgen deficiency; no prostate cancer suspected.

Design outcomes

Primary

Measure	Time frame
Date of the maximum apoptosis in the prostate tissues treated by finasteride	—

Secondary

Measure	Time frame
Molecular mechanisms involved in BPH finasteride induced apoptosis	—
Decrease in the frequency of the hemorrhagic incidents after the surgical procedure in patients with a treatment using finasteride	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026